CAS No. |
185246-32-6 |
中文名称 |
3-[(2R,4aR,6R,7R,7aS)-7-羟基-2-氧代-2-(硫代钠基)-六氢-2λ-呋喃并[3,2-d][1,3,2]二氧杂膦杂环辛烷-6-基]-2-溴-6-苯基-3H,4H,9H-咪唑并[1,2-a]嘌呤-9-酮 |
英文名称 |
3-[(2R,4aR,6R,7R,7aS)-7-hydroxy-2-oxo-2-(Sodiosulfanyl)-hexahydro-2λ-furo[3,2-d][1,3,2]dioxaphosphinin-6-yl]-2-bromo-6-phenyl-3H,4H,9H-imidazo[1,2-a]purin-9-one |
别名 |
RP-8-BROMO-BETA-PHENYL-1,N2-ETHENOGUANOSINE 3',5'-CYCLIC MONOPHOSPHOROTHIOATE SODIUM SALT HYDRATE;Rp-8-Bromo-β-phenyl-1,N2-ethenoguanosine 3μ:5μ-cyclic monophosphorothioate hydrate sodium salt;Rp-8-Br-PET-cGMPS hydrate, Rp-β-Phenyl-1,N2-etheno-8-bromoguanosine 3μ,5μ-cyclic monophosphorothioate hydrate sodium salt;Rp-8-bromo-PET-Cyclic GMPS (sodium salt);Rp-8-Bromo-β-phenyl-1,N2-ethenoguanosine 3′,5′-cyclic monophosphorothioate;Rp-8-Bromo-beta-phenyl-1,N2-ethenoguanosine 3',5'-cyclic monophosphorothioate sodium salt;Rp-8-Bromo-beta-phenyl-1,N2-ethenoguanosine 3',5'-cyclic monophosphorothioate sodium salt >=98% (HPLC), powder;Rp-8-bromo-PET-Cyclic GMPS sodium |
标准英文名 |
sodium (4aR,6R,7R,7aS)-6-(2-bromo-9-oxo-6-phenyl-4,9-dihydro-3H-imidazo[1,2-a]purin-3-yl)-7-hydroxytetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphinine-2-thiolate 2-oxide |
分子式 |
C18H14BrN5NaO6PS |
分子量 |
562.27
|
精确分子量 |
560.95
|
SMILES |
BrC1=NC(C(N2C(N3)=NC(C4=CC=CC=C4)=C2)=O)=C3N1[C@@]5([H])[C@@H]([C@@]6([H])[C@](COP([S-])(O6)=O)([H])O5)O.[Na+] |
标准SMILES |
[Na+].O[C@H]1[C@@H](O[C@@H]2COP(=O)([S-])O[C@H]21)N1C2NC3=NC(=CN3C(=O)C=2N=C1Br)C1=CC=CC=C1 |
用途 |
Rp-8-Br-PET-cGMPS (sodium salt) is a cell-permeable, competitive, and reversible inhibitor of cGMP-dependent protein kinases (cGK), effectively blocking cGMP-mediated activation of cGKI and cGKII (Kis = 35 and 30 nM, respectively); it acts as a partial agonist of cGKI in the absence of cGMP stimulation (Ki = 1 μM); it exhibits weaker inhibitory effects on protein kinase A (Ki = 11 μM) and cGMP-induced cyclic nucleotide-gated channel activation (IC50 = 25 μM); it is resistant to hydrolysis by phosphodiesterase 11. |
InChIKey |
SVMPQLHYWRTQCX-WKKXCKAJSA-M |